| Literature DB >> 33589636 |
Yannic C Bartsch1, Stephanie Fischinger1,2, Sameed M Siddiqui3,4, Zhilin Chen1, Jingyou Yu1,5, Makda Gebre1,5, Caroline Atyeo1, Matthew J Gorman1, Alex Lee Zhu1, Jaewon Kang1, John S Burke1, Matthew Slein1, Matthew J Gluck6,7, Samuel Beger6, Yiyuan Hu6, Justin Rhee6, Eric Petersen6, Benjamin Mormann6, Michael de St Aubin8, Mohammad A Hasdianda9, Guruprasad Jambaulikar9, Edward W Boyer9, Pardis C Sabeti4,10,11,12, Dan H Barouch1,5,12, Boris D Julg1, Elon R Musk6, Anil S Menon13, Douglas A Lauffenburger14, Eric J Nilles15, Galit Alter16,17.
Abstract
Antibodies serve as biomarkers of infection, but if sustained can confer long-term immunity. Yet, for most clinically approved vaccines, binding antibody titers only serve as a surrogate of protection. Instead, the ability of vaccine induced antibodies to neutralize or mediate Fc-effector functions is mechanistically linked to protection. While evidence has begun to point to persisting antibody responses among SARS-CoV-2 infected individuals, cases of re-infection have begun to emerge, calling the protective nature of humoral immunity against this highly infectious pathogen into question. Using a community-based surveillance study, we aimed to define the relationship between titers and functional antibody activity to SARS-CoV-2 over time. Here we report significant heterogeneity, but limited decay, across antibody titers amongst 120 identified seroconverters, most of whom had asymptomatic infection. Notably, neutralization, Fc-function, and SARS-CoV-2 specific T cell responses were only observed in subjects that elicited RBD-specific antibody titers above a threshold. The findings point to a switch-like relationship between observed antibody titer and function, where a distinct threshold of activity-defined by the level of antibodies-is required to elicit vigorous humoral and cellular response. This response activity level may be essential for durable protection, potentially explaining why re-infections occur with SARS-CoV-2 and other common coronaviruses.Entities:
Year: 2021 PMID: 33589636 DOI: 10.1038/s41467-021-21336-8
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919